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Abstract 
A simple, accurate, sensitive and reproducible visible spectrophotometric method has been developed for the 
determination of Tulobuterol (TLB) in bulk and also in its pharmaceutical dosage formulations. The proposed 
method was based on complexation of the drug with Bromo Cresol Green (BCG) extracted with chloroform 
showing absorbance maxima at 624 nm respectively. Beer's law is obeyed over a concentration range of 0.1-
0.8µg/mL. The respective linear regression equation being Y (0.0309) =1.065x +0.0396 for TLB. Results of 
analysis for the method established, was validated statistically and also by recovery studies. The color was 
stable for about 1½ hour. The apparent molar absorptivity and Sandell’s Sensitivity values are 0.43x104 Lmol-
1cm-1 and 0.7674µgcm-2 respectively. The assay and recovery studies were found to be 101.43% and 
coefficient correlation(r) was found to be0.994.The different experimental parameters effecting the 
development and stability were studied carefully and optimized. No interference was observed in the presence 
of common pharmaceutical excipients. The validity of the methods was tested by analyzing the drug in its 
pharmaceutical preparations. Good recoveries were also obtained. The developed method employed was 
successful for the determination of TLB in various pharmaceutical preparations. 
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1. Introduction 
Tulobuterol (TLB) (Empirical Formula: C12H16ClNO, 
Mol.Weight: 227.730 g/mol) chemically is, (RS)-2-
(tert-butylamino)-1-(2-chlorophenyl) Ethanol. 
(Figure: 1). Chronic Obstructive Pulmonary Disease 
(COPD) is an inflammatory lung disease that occurs 
as a result of inhalation of harmful particles, such as 
those in cigarette smoke. There is some concern that 
the number of COPD patients will increase with the 
aging of the population. The global initiative for 
Chronic Obstructive Lung Disease (COLD) 
recommends the use of long-acting bronchodilators1-5, 
such as anti cholinergics, β2 adrenergic receptor 
agonists and methyl xanthenes for the management of 
stable COPD patients. TLB is a direct-acting 
sympathomimetic with selective action on β2-
receptors. Thus, TLB is a selective β2 adrenergic 
agonist with minimal nonselective inhibitory effect6-9 
on airway and vascular smooth muscle. It also 
facilitates adrenergic neurotransmission, which may 
help to explain its bronchodilator effect in the intact 
organism. TLB does not activate β1 adrenoceptors and 
has no direct positive chronotropic effect10-13. As 
highlighted earlier, the use of the above drug has 
become, very wide spread. The survey of literature 
showed a very few chromatographic methods and 
biological analytical methods14-18 irrespective of any 
single spectrophotometric method for the analysis of 
selected drug at the time of commencement of these 
investigations. So in order to bridge this gap the 
authors are fascinated in choosing this drug. A 
detailed account of all analytical methods existing for 
the drug is made to avoid duplication of the method 
developed. The authors has made some humble 
attempts, hoping to fulfill and bridge this gap, in 
succeeding the developed extractive analytical 
method by using spectrophotometry, verifying the 
efficacy and safety of TLB. The results of this labor 
of love are set forth in this article. 
 
Figure 1: Tulobuterol 
 
2. Experimental: 
2.1 Materials & methods 
2.1.1 Instrument: Shimadzu double beam Ultra 
Violet –Visible Spectrophotometer UV-1800 with 1 
cm matched quartz cells were used for all spectral 
measurements. 
2.1.2 Chemicals & Reagents: All the chemicals used 
were of analytical & extra pure reagent grade, 
procured from SD Fine Chemicals (SDFC), Mumbai, 
India. All the solutions were freshly prepared. 
1. Acid Phthalate Buffer pH 2.4 
2. Bromo Cresol Green-BCG (0.1%) 
3. Chloroform AR grade 
4. Distilled Water 
5. Hydrochloric Acid 
6. Methanol AR grade 
7. Potassium Hydrogen Phthalate EP 
2.2 Preparative Analytical Methodology 
2.2.1 Preparation of Phthalate buffer pH 2.4: Add 
250 ml of 0.2 M potassium Hydrogen Phthalate to 10 
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ml of 0.2 M HCL make up the final volume with 
water to produce 1000 ml. 
2.2.2 Preparation of 0.1% Bromo Cresol Green 
(BCG) dye solution: Weigh 0.1 gm of dye sample 
and dissolve in small quantity of distilled water and 
make up to 100 ml and filter it using filter paper if 
necessary. 
2.2.3 Procedure 
2.2.3.1 Preparation of standard stock and working 
sample solution: 
 Weigh 0.5 gm of bulk drug (TLB) and dissolve in 50 
ml of methanol, shake well till it dissolves and make 
up to 100 ml with the same. From the above stock 
solution, working sample solution was prepared from 
0.1-0.8 ml (1-8/ml) respectively. 
2.2.3.2  Assay 
Aliquots of standard drug solution of TLB containing 
0.1-0.8 ml (1-8 µg/mL) were taken and transferred 
into series of separating funnels. To each separating 
funnel, 2 ml of BCG,  2 ml of Phthalate buffer pH 2.4 
and 5 ml of chloroform were added. The contents are 
shaken thoroughly for 5 min and allowed to stand for 
15 minutes, so as to separate the aqueous and 
chloroform layer for the formation of colored ion 
association complex. The absorbance of the yellow 
colored chromogen was measured at 624 nm against 
reagent blank and a calibration curve was constructed. 
The absorbance of the sample solution was measured, 
and the amount of TLB was determined by referring 
to the calibration curve or computed from the 
regression equation as illustrated in Figure 2 & 3. 
 
Figure: 2: Absorption spectrum of TLB with BCG 
 
 
Fig: 3: Standard Calibration Curve of TLB in 
Presence of BCG Reagent 
 
2.3.3 Preparation of the sample solution 
Ten tablets of TLB were accurately weighed and 
powdered. Tablet powder equivalent to 100 mg of 
TLB was dissolved in 50 ml of methanol, sonicated 
for 15 mins and filtered. The filtrate is combined 
and the final volume was made to 100 ml with 
methanol for the above method. The solution was 
suitably diluted and analyzed as given under the 
assay procedure for bulk sample and the linearity 
absorbance range observed for TLB was shown in 
Table 1. The analysis procedure was repeated three 
times with tablet formulations and the result of 
analysis was determined as depicted and shown in 
Table 2. 
Table 1: Linearity absorbance range of TLB 
Concentration(µg/mL) Absorbance 
0.1 0.14 
0.2 0.25 
0.4 0.33 
0.6 0.47 
0.8 0.77 
 
2.4 Recovery Studies 
To ensure the accuracy and reproducibility of the 
results obtained, known amounts of the pure drug was 
added to the previously analyzed formulates samples 
and these samples were reanalyzed by the proposed 
method and also by performing recovery studies. The 
percentage recoveries, thus obtained for this method 
were given in Table 2. 
 
Table 2: Assay & recovery studies of TLB in tablet formulation 
Tablet Formulation Amount Claim (mg/tablet) 
*Amount obtained(mg) 
by the proposed method
**% Recovery by the 
proposed method 
1 5 4.93 102.28 
2 5 4.82 101.19 
3 5 4.87 100.83 
 
*Average of three determinations                                  **After spiking the sample 
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3. Results And Discussions 
The extractive spectrophotometric methods are more 
popular due to their sensitivity in assay of the drug 
and hence, ion pair extractive spectrophotometric 
methods have gained considerable attention for 
quantitative determination of many pharmaceutical 
preparations. These proposed methods are extractive 
spectrophotometric methods for the determination of 
TLB by using chloroform as a solvent form in its 
formulation i.e. tablets. The color ion-pair association 
complexes formed is very stable. The working 
conditions of this method were established by varying 
one parameter at a time and keeping the other 
parameters fixed by observing the effect produced on 
the absorbance of the color species. Various 
parameters involved for maximum color development 
for this method were optimized. The proposed 
methods were validated statistically and by recovery 
studies. The molar absorptivity and Sandell’s 
sensitivity values show the sensitivity of methods 
while the precision was confirmed by % RSD 
(Relative Standard Deviation). The optical 
characteristics such as absorption maxima (nm), 
molar absorptivity (lit. mol -1 cm-1), correlation 
coefficient (r) and Sandell’s sensitivity 
(mg/cm2/0.001) were calculated and are also 
summarized in Table 3. Assay results of recovery 
studies are given in Table 2.                                                      
Results are in good agreement with labeled values. 
The percent recovery obtained indicates non-
interference from the common excipients used in the 
formulation. The reproducibility, repeatability and 
accuracy of these methods were found to be good, 
which is evidenced by low standard deviation. The 
proposed method is simple, sensitive, accurate, 
precise and reproducible. These are directly applied to 
the drug to form chromogen. Hence, they can be 
successfully applied for the routine estimation of TLB 
in bulk and pharmaceutical dosage form even at very 
low concentration and determination of stability of 
drug in formulation such as tablets. 
Table 3: Optical Characteristics and Regression 
Analysis of the Proposed Method 
Parameters Proposed method
Measured λmax (nm) 624 
Beers law limit (µg/mL) 0.1-0.8 
Molar absorptivity 
(L/mole/cm) 0.43x10
4 
Sandell’s sensitivity 
(mcg/cm2/0.001 Absorbance unit) 0.7674 
Regression Equation(Y = mx + c) Y (0.0309) =1.065x +0.0396 
Slope (m) 1.065 
Intercept (c) 0.0309 
Standard Error of Estimate 0.0396 
Correlation coefficient (r) 0.994 
Precision (% Relative standard 
deviation) 0.3068 
Color stability (hours) 1hr 30 min 
Confidence intervals (upper limit 
=1) 0.909-0.794 
LOD (µg/ml) 0.07 
LOQ (µg/ml) 0.21 
4. Conclusion 
TLB was estimated successfully by the developed 
extractive spectrophotometric method, both as a pure 
compound and also the constituent of a tablet 
formulation. The method is simple, rapid, accurate, or 
cost-effective with high accuracy & precision and 
does not involve any critical reaction conditions, or 
tedious sample preparation. It is unaffected by slight 
variations in experimental conditions such as pH, dye 
concentration, shaking time and temperature. The 
applicability of the new procedure for routine quality 
control of TLB in pharmaceutical formulations was 
established.  
The results of this labor of love are set forth by 
developing a simple, precise and accurate method for 
the estimation of TLB in bulk drug sample and also in 
its pharmaceutical dosage forms, used for routine 
analysis of TLB. 
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